A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Zentalis Pharmaceuticals, Inc.
ZNTL
$308M
Mkt Cap
$4.33
-2.70%
Zentalis Pharmaceuticals, Inc. (ZNTL) has a 5-year average return on invested capital (ROIC) of -58.0%. This is below average and may indicate limited pricing power.
Zentalis Pharmaceuticals, Inc. (ZNTL) has a market capitalization of $313M. It is classified as a small-cap stock.
Zentalis Pharmaceuticals, Inc. (ZNTL) does not currently pay a regular dividend.
Zentalis Pharmaceuticals, Inc. (ZNTL) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Zentalis Pharmaceuticals, Inc. (ZNTL) generated $-171 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Zentalis Pharmaceuticals, Inc. (ZNTL) has a debt-to-equity ratio of 0.28. This indicates a conservatively financed balance sheet.
Zentalis Pharmaceuticals, Inc. (ZNTL) reported earnings per share (EPS) of $-2.33 in its most recent fiscal year.
We are a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. We are currently focused on advancing the clinical development of azenosertib in Cyclin E1+ platinum-resistant ovarian cancer, or PROC. We believe that our DENALI (ZN-c3-005) Part 2 clinical trial of azenosertib in patients with Cyclin E1+ PROC, if successful, has the potential to support an accelerated approval, subject to U.S. Food and Drug Administration, or FDA, review. Azenosertib also has broad franchise potential beyond Cyclin E1+ PROC. We exclusively in-license or solely own worldwide development and commercialization rights to azenosertib.
| Segment | 2024 | % of Total |
|---|---|---|
Reportable Segment | $67M | 100% |
| Metric | TTM | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | 0 | - | 0 |
| Net Income | -149M | -166M | -292M |
| EPS | $-2.08 | $-2.33 | $-4.47 |
| Free Cash Flow | 0 | -171M | -208M |
| ROIC | -61.1% | -49.2% | -66.8% |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | 0.28 | 0.26 |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -165M | -191M | -300M |
| Operating Margin | 0.0% | - | - |
| ROE | -59.0% | -42.8% | -66.8% |
| Shares Outstanding | 72M | 71M | 65M |
| Metric | |||
|---|---|---|---|
| Income Statement | |||
| Revenue | 0 | N/A | 0 |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -300M | -191M | -165M |
| Op. Margin | N/A | N/A | 0.0% |
| Net Income | -292M | -166M | -149M |
| Net Margin | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 3.7M | 3.7M |
| Returns on Capital | |||
| ROIC | -66.8% | -49.2% | -61.1% |
| ROE | -66.8% | -42.8% | -59.0% |
| ROA | -53.0% | -33.8% | -45.6% |
| Cash Flow | |||
| Op. Cash Flow | -208M | -171M | -134M |
| Free Cash Flow | -208M | -171M | 0 |
| Owner Earnings | -264M | -239M | -203M |
| CapEx | 583K | 221K | 0 |
| Maint. CapEx | 1.4M | 1.3M | 1.3M |
| Growth CapEx | 0 | 0 | 0 |
| D&A | 1.4M | 1.3M | 1.3M |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 55M | 67M | 67M |
| Debt Repayment | 0 | 0 | 0 |
| Balance Sheet | |||
| Net Debt | N/A | N/A | -39M |
| Cash & Equiv. | N/A | N/A | 39M |
| Long-Term Debt | N/A | N/A | N/A |
| Debt/Equity | 0.26 | 0.28 | 0.00 |
| Interest Coverage | N/A | N/A | N/A |
| Equity | 437M | 337M | 253M |
| Total Assets | 552M | 430M | 327M |
| Total Liabilities | 114M | 93M | 74M |
| Intangibles | 3.7M | N/A | N/A |
| Retained Earnings | -889M | -1.1B | -1.1B |
| Working Capital | 427M | 333M | 333M |
| Current Assets | 497M | 386M | 386M |
| Current Liabilities | 69M | 53M | 53M |
| Per Share Data | |||
| EPS | -4.47 | -2.33 | -2.08 |
| Owner EPS | -4.04 | -3.36 | -2.80 |
| Book Value | 6.69 | 4.74 | 3.50 |
| Cash Flow/Share | -3.18 | -2.40 | -2.05 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 65.4M | 71.2M | 72.3M |
| Valuation | |||
| P/E Ratio | N/A | N/A | -2.1 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | 2.3 | 0.6 | 1.2 |
| Price/Sales | N/A | N/A | N/A |
| FCF Yield | -20.5% | -78.6% | N/A |
| Market Cap | 1.0B | 218M | 313M |
| Avg. Price | 21.04 | 7.94 | 4.33 |
| Year-End Price | 15.58 | 3.06 | 4.33 |
Zentalis Pharmaceuticals, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Zentalis Pharmaceuticals, Inc. (ZNTL) has a return on equity (ROE) of -42.8%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 2 years of financial data for Zentalis Pharmaceuticals, Inc. (ZNTL), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Zentalis Pharmaceuticals, Inc. (ZNTL) has a book value per share of $4.74, based on its most recent annual SEC filing.